Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Breast Neoplasms|HER2-positive Breast Cancer|Stage II Breast Cancer|Stage IIIA Breast Cancer
Interventions: BIOLOGICAL: TX05 (trastuzumab)|BIOLOGICAL: Herceptin®|DRUG: Paclitaxel|DRUG: Epirubicin|DRUG: Cyclophosphamide
Sponsor: Tanvex BioPharma USA, Inc.